MeSH term
Frequency | Condition_Probility | Adolescent | 38 | 0.0 |
Child | 34 | 0.0 |
Child, Preschool | 27 | 0.0 |
Female | 49 | 0.0 |
Gliadin/immunology | 14 | 70.0 |
Humans | 94 | 0.0 |
Immunoglobulin A/blood | 9 | 8.0 |
Male | 45 | 0.0 |
Adult | 32 | 0.0 |
Aged | 16 | 0.0 |
Autoantibodies/blood | 3 | 1.0 |
Biological Markers/blood | 8 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Mass Screening/methods | 3 | 6.0 |
Middle Aged | 24 | 0.0 |
Muscle Fibers/immunology | 3 | 60.0 |
Prospective Studies | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 48 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Autoantibodies/*blood | 9 | 3.0 |
Comparative Study | 12 | 0.0 |
Disease Progression | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 13 | 0.0 |
Prognosis | 2 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Binding Sites | 3 | 0.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Ligands | 3 | 0.0 |
Lysosomal Storage Diseases/enzymology/*genetics | 4 | 100.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Molecular Sequence Data | 12 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Protein Conformation | 3 | 0.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Transfection | 3 | 0.0 |
Celiac Disease/*complications/diagnosis/epidemiology | 2 | 100.0 |
Cross-Sectional Studies | 2 | 0.0 |
Prevalence | 9 | 0.0 |
Antibodies/*blood | 5 | 11.0 |
Celiac Disease/*diagnosis | 2 | 50.0 |
Immunoglobulin A/*blood | 3 | 11.0 |
Muscle Fibers/*immunology | 6 | 85.0 |
Reticulin/*immunology | 3 | 100.0 |
Transglutaminases/*immunology | 4 | 57.0 |
English Abstract | 12 | 0.0 |
Infant | 19 | 0.0 |
Sensitivity and Specificity | 10 | 0.0 |
Celiac Disease/*blood/immunology | 2 | 66.0 |
Cohort Studies | 2 | 0.0 |
Transglutaminases/immunology | 2 | 28.0 |
Gestational Age | 4 | 0.0 |
*Infant, Small for Gestational Age | 3 | 17.0 |
Pregnancy | 4 | 0.0 |
Retrospective Studies | 5 | 0.0 |
Acetylglucosamine/*analogs & derivatives/urine | 6 | 100.0 |
Animals | 9 | 0.0 |
Liver/pathology | 2 | 1.0 |
Mice | 3 | 0.0 |
Duodenum/*pathology | 2 | 33.0 |
Predictive Value of Tests | 6 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gliadin/*immunology | 21 | 67.0 |
Gluten/administration & dosage | 2 | 25.0 |
Celiac Disease/*immunology | 5 | 26.0 |
Saliva/*immunology | 2 | 11.0 |
Family Health | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 7 | 0.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Follow-Up Studies | 4 | 0.0 |
Gliadin/blood/*immunology | 2 | 100.0 |
Immunoglobulin A/blood/*immunology | 2 | 40.0 |
Sweden/epidemiology | 2 | 1.0 |
Finland | 3 | 1.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Antibodies/analysis | 2 | 1.0 |
Biopsy | 4 | 0.0 |
Celiac Disease/*diagnosis/immunology | 3 | 100.0 |
Immunoglobulin A/*analysis | 4 | 7.0 |
Antibodies/blood | 4 | 6.0 |
Calreticulin | 2 | 8.0 |
Chromatography, Affinity | 2 | 0.0 |
Gliadin/chemistry/*immunology | 2 | 66.0 |
Infant, Newborn | 7 | 0.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Aspartylglucosylaminase/chemistry/genetics/*metabolism | 2 | 100.0 |
Catalysis | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Phosphorylation | 2 | 0.0 |
Blood Donors/*statistics & numerical data | 2 | 66.0 |
Random Allocation | 2 | 0.0 |
Mutation | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 3 | 0.0 |
Leukocyte Count | 4 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Celiac Disease/blood/*immunology | 3 | 60.0 |
Aspartylglucosylaminase/deficiency/*genetics | 2 | 100.0 |
*Disease Models, Animal | 2 | 0.0 |
Phenotype | 4 | 0.0 |
Intestine, Small/pathology | 2 | 11.0 |
Aspartylglucosylaminase/*deficiency/genetics | 4 | 100.0 |
Leukocytes/enzymology | 2 | 1.0 |
DNA Mutational Analysis | 2 | 0.0 |
Lysosomes/*enzymology | 3 | 6.0 |
Protein Binding | 3 | 0.0 |
Aspartylglucosylaminase/*genetics | 3 | 100.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Immunoglobulin G/blood | 4 | 1.0 |
Mutagenesis | 2 | 0.0 |
Antibodies/*analysis | 6 | 5.0 |
Mass Screening/*methods | 3 | 5.0 |
Serologic Tests/methods | 3 | 23.0 |
Autoimmunity | 2 | 1.0 |
Immunoglobulin G/blood/immunology | 2 | 4.0 |
Body Composition | 2 | 0.0 |
*Body Weight | 2 | 3.0 |
Fetal Growth Retardation/*physiopathology | 2 | 20.0 |
Genetic Markers | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
Genotype | 2 | 0.0 |
*Point Mutation | 2 | 0.0 |
Duodenum/pathology | 2 | 22.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Leukocytes/*enzymology | 2 | 3.0 |
Macromolecular Substances | 3 | 0.0 |
Molecular Weight | 2 | 0.0 |
DNA | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cell Line | 2 | 0.0 |
Cells, Cultured | 3 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Gluten/*adverse effects | 2 | 66.0 |
Lymphocytes/pathology | 2 | 2.0 |
Immunoglobulin G/*analysis | 3 | 4.0 |
Plant Proteins/*immunology | 6 | 28.0 |
Gluten/immunology | 2 | 50.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Immunologic Tests | 2 | 6.0 |
Jejunum/pathology | 4 | 36.0 |
Granulocytes/*immunology | 2 | 5.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Dermatitis Herpetiformis/diet therapy/*immunology/pathology | 2 | 100.0 |
